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pAtherosclerosis is largely an inflammatory disorder
marked by infiltration of monocytes into the arterial
wall (1,2). Activated macrophages produce proin-
flammatory cytokines and contribute to lesion pro-
gression, adding to the lipid-rich necrotic core and
(via the production of degradative enzymes) thin-
ning of the fibrous cap. Indeed, the predominant
theory of atherosclerosis holds that inflammation
plays a critical role in all phases of atherosclerosis,
from initiation, to progression, to subsequent
atherothrombosis. As a result, intense interest has
focused on methods that could be used to report
changes in inflammation within the arterial wall as
a way to risk-stratify patients or to evaluate the
effects of pharmacologic therapies.
See pages 1100 and 1110
Positron emission tomography (PET) has
emerged as an important tool in this respect because
it can be used noninvasively, uses a U.S. Food and
Drug Administration–approved imaging agent
(18F-2-deoxy-D-glucose [FDG]), and is currently
used for cancer detection imaging. FDG uptake
reflects the rate of glycolysis, which is higher in
areas containing metabolically active tumor cells
and in inflamed tissues. Several clinical studies have
shown high FDG accumulation in human athero-
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Jude Medical.clerotic arteries, with uptake of deoxyglucose in
acrophage-rich regions and positive correlations
etween FDG uptake and the amount of immuno-
istochemical staining and gene expression for
acrophage-specific markers (3–7). Indeed, the
ink between macrophage activation and enhanced
lycolysis is well established by a body of research
hat spans nearly a century (8). A large body of
vidence from research in basic cellular physiology
emonstrates that activated macrophages have an
nusually high metabolic rate (9,10) and avidly
ccumulate FDG (11). Glycolysis is further stimu-
ated by classic or innate activation pathways (but
ot by alternative pathways) (12). However, in a
ecent report (13), the investigators proposed that
ypoxia, more so than cytokine stimulation, plays an
mportant role in the induction of glycolysis within
acrophages in culture. Hence, the exact mechanism
inking macrophage activation to enhanced glycolysis
nd increased arterial FDG uptake remains an area of
ngoing investigation. These considerations notwith-
tanding, FDG imaging represents an important tool
or assessment of inflammatory responses to anti-
therogenic compounds.
The arterial PET signal might also be clinically
eaningful. Several studies have shown a connec-
ion between the FDG signal and clinical risk
actors or risk scores (14–17). Additionally, arterial
DG uptake is higher soon after stroke (3) and
yocardial infarction (18). Furthermore, a link
etween arterial FDG uptake and risk for subse-
uent clinical events is being actively investigated.
small number of studies have so far reported that
igher arterial FDG uptake is associated with
ubstantially increased risk for subsequent stroke
nd myocardial infarction (19,20). However, large
rospective studies will be needed to further define
he potential clinical utility of arterial FDG PET.
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1120In the meantime, the use of FDG PET for
imaging trials is becoming well established. The
initial human experience with FDG PET for as-
sessing treatment efficacy was initially limited to
evaluation of statins. In 2 prior single-center trials,
statin therapy resulted in a significant reduction in
arterial FDG uptake after 3 months (21,22). Those
studies provided glimpses into the possibility of
using FDG PET for the evaluation of therapeutic
efficacy. However, the fact that they were single-
center experiences and limited to only 1 class of
drugs raised the question of whether FDG PET
could be useful in a multicenter trial setting and for
the evaluation of drugs other than statins. For those
questions, the recently published dal-PLAQUE
study (23) provided important answers. That study
reported on the use of PET and magnetic resonance
imaging (MRI) to evaluate the safety and efficacy
of dalcetrapib, a novel high-density lipoprotein
(HDL)–raising cholesterol ester transfer protein
antagonist. In that multicenter trial, dalcetrapib was
associated with a significant attenuation in vascular
remodeling at 2 years, as assessed by MRI. Inter-
estingly, although the increase in HDL concentra-
tion did not correlate with changes in arterial wall
remodeling, increases in HDL concentrations did
correlate with reductions in carotid inflammation
(by PET). Moreover, the reduction in arterial
inflammation seen as early as 6 months was correlated
with the subsequent reduction in vascular remodeling
seen at 2 years. Hence the combined use of PET and
MRI produced complementary information and pro-
vided useful insights into the potential utility of
HDL-raising strategies. Several completed and ongo-
ing trials have used or are using FDG PET to evaluate
the effect of novel drugs directed against arterial
inflammation. The results of a number of those
studies are expected over the next several months.
In this issue of iJACC, 2 reports (24,25) provide
insight into the ability of combined PET and
computed tomography (CT) to measure changes in
arterial inflammation in response to the diabetes
drug pioglitazone, a peroxisome proliferator-
activated receptor gamma agonist. Pioglitazone has
multiple favorable metabolic effects, including de-
creasing plasma glucose and improving lipid profiles
in patients with insulin resistance. Several large
clinical studies have suggested a clinical benefit for
pioglitazone in reducing vascular events in patients
with type 2 diabetes. However, it remains unknown
whether its potentially beneficial effects are in part
related to decreasing inflammatory burden of
plaques or other effects.The study by Vucic et al. (24) was designed to
address that question. In their study, PET-CT and
MRI were used to evaluate the arterial walls of
animals made atherosclerotic after prolonged high
fat exposure. The investigators report that although
arterial wall FDG uptake was increased in control
animals (on a hyperlipidemic diet alone), FDG
uptake values remained stable in animals treated with
pioglitazone. Immunohistochemistry of aortas dem-
onstrated a relative decrease in tissue macrophages and
oxidized phospholipid immunoreactivity in the piogli-
tazone group, while there was no change in metabolic
parameters between groups. The investigators report a
strong positive correlation between FDG uptake and
macrophage density (thus providing further confirma-
tion for several prior human and animal studies) and
provide novel data showing that the dynamic contrast-
enhanced MRI “area under the curve” parameter
correlated with neovessel (but not macrophage) den-
sity. Thus, the study sheds light on the possible
complementary role of the 2 methodologies, with
FDG PET providing insights about changes in in-
flammation and MRI providing data about structural
changes and changes in neovessels.
In the second PET study reported in this issue,
Mizoguchi et al. (25) present the results of a
single-center, double-blinded, placebo-controlled
study evaluating the effect of pioglitazone on the
blood vessel wall in humans. In that study, patients
with glucose intolerance or type 2 diabetes and
carotid atherosclerosis were randomized to either
pioglitazone or glimepiride. Patients randomized to
either agent had evidence of reductions in both
fasting glucose and glycosylated hemoglobin levels.
However, pioglitazone alone was associated with
significantly increased HDL cholesterol, decreased
C-reactive protein, and a reduction in arterial FDG
uptake. Multiple stepwise regression analysis dem-
onstrated that the increase in HDL cholesterol
levels was independently correlated with attenua-
tion of plaque inflammation.
In summary, both reports suggest that pioglitazone
either indirectly or directly reduces plaque macro-
phage inflammatory activity. Considerable data sup-
port multiple mechanisms for the effect of peroxisome
proliferator-activated receptor gamma in reducing
macrophage recruitment, including direct effects of
these agents in inhibiting macrophage inflammatory
gene expression (26). Conditional knockout of
macrophage-specific peroxisome proliferator-activated
receptor gamma in atherosclerosis-prone mice re-
sults in increased macrophage atherosclerotic lesion
content. Thus, the findings of both studies are
k
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1121consistent with expectations given the known
mechanisms of pioglitazone.
These studies underscore the value of FDG
imaging for monitoring inflammatory changes
within plaques. However, it is important to note
that it remains unclear whether lowering plaque
inflammation is the mechanism by which statins
and pioglitazone therapy decrease cardiovascular
events or even whether, in general, reductions in
inflammation would translate into clinical benefit.
Thus, demonstrating a reduction in arterial inflam-
mation may not always predict eventual efficacy.
Instead, the potential for eventual clinical success of
a novel drug should be assessed by tapping into a
much broader database of information. This could
be achieved by combining FDG PET assessment
with imaging of arterial wall structure (e.g., with
MRI to evaluate remodeling or plaque progression),
a carefully chosen panel of blood marker data, along
with thorough monitoring for off-target effects.
Then, if the sum of the data suggests benefit,
graduation to a phase III clinical endpoint trial
could be pursued with greater confidence. It should
also be noted that typical trials of PET-CT are
conducted with 50 to 150 patients and with 3 to 6
months of observation. This evaluation of changesEndovasc Surg 2009;37:714–21.
1
1
1
tween innate, classitively short period. Thus, although the technology
cannot replace large-scale clinical endpoint trials,
FDG PET (in combination with MRI or CT) may
prove useful for identifying the most promising
therapeutics, which in turn could be promoted more
efficiently through the drug development process.
The PET studies in this issue provide additional
insights into the value of noninvasive imaging of the
artery wall. With continued standardization and after
further study against clinical endpoints, noninvasive
imaging with PET, possibly in combination with
MRI and/or CT, might prove useful for the refine-
ment of clinical risk (although demonstration of cost
efficacy may prove a particularly daunting challenge).
Furthermore, a multimodal imaging strategy that
includes PET-CT, by reporting on the biochemical
and structural changes in the arterial wall during phase
II clinical trials, might provide for a more efficient and
cost-effective drug discovery process, all in the hope of
eventually yielding new therapies and better outcomes
for patients with atherosclerosis.
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